Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eye Infections, Bacterial | 4 | 2017 | 239 | 0.790 |
Why?
|
| Encephalitis, Tick-Borne | 1 | 2022 | 37 | 0.790 |
Why?
|
| Encephalitis Viruses, Tick-Borne | 1 | 2022 | 43 | 0.780 |
Why?
|
| Cornea | 7 | 2020 | 1326 | 0.700 |
Why?
|
| Encephalitis | 1 | 2022 | 438 | 0.610 |
Why?
|
| Biofilms | 3 | 2016 | 621 | 0.600 |
Why?
|
| Eye Infections, Fungal | 3 | 2020 | 100 | 0.540 |
Why?
|
| Virus Diseases | 1 | 2022 | 719 | 0.520 |
Why?
|
| Endophthalmitis | 2 | 2020 | 257 | 0.520 |
Why?
|
| Thromboembolism | 1 | 2022 | 996 | 0.500 |
Why?
|
| Bioartificial Organs | 1 | 2014 | 47 | 0.450 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2020 | 642 | 0.440 |
Why?
|
| Vaccines | 1 | 2022 | 832 | 0.440 |
Why?
|
| Polyethyleneimine | 1 | 2011 | 67 | 0.380 |
Why?
|
| Prostheses and Implants | 6 | 2016 | 1270 | 0.380 |
Why?
|
| Endocarditis, Bacterial | 2 | 2023 | 442 | 0.330 |
Why?
|
| Endocarditis | 2 | 2023 | 349 | 0.330 |
Why?
|
| Artificial Organs | 3 | 2016 | 149 | 0.310 |
Why?
|
| Thrombosis | 1 | 2022 | 2929 | 0.300 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2008 | 119 | 0.300 |
Why?
|
| Staphylococcus aureus | 2 | 2011 | 1460 | 0.260 |
Why?
|
| Biocompatible Materials | 3 | 2013 | 1688 | 0.240 |
Why?
|
| Keratitis | 3 | 2017 | 239 | 0.240 |
Why?
|
| Corneal Diseases | 3 | 2016 | 536 | 0.220 |
Why?
|
| Epithelium, Corneal | 2 | 2016 | 249 | 0.220 |
Why?
|
| Prosthesis-Related Infections | 1 | 2008 | 486 | 0.220 |
Why?
|
| Fusarium | 2 | 2020 | 51 | 0.200 |
Why?
|
| Myelitis | 1 | 2022 | 49 | 0.200 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2022 | 126 | 0.180 |
Why?
|
| Rabbits | 7 | 2017 | 4772 | 0.170 |
Why?
|
| Titanium | 2 | 2013 | 484 | 0.170 |
Why?
|
| Aspergillus fumigatus | 1 | 2020 | 156 | 0.170 |
Why?
|
| Prosthesis Implantation | 2 | 2014 | 590 | 0.160 |
Why?
|
| Salmonella typhimurium | 5 | 1995 | 344 | 0.160 |
Why?
|
| New England | 1 | 2022 | 1053 | 0.160 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2023 | 529 | 0.160 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2016 | 940 | 0.150 |
Why?
|
| Epidemics | 1 | 2023 | 512 | 0.150 |
Why?
|
| Candida albicans | 1 | 2020 | 374 | 0.150 |
Why?
|
| Bacteria | 1 | 2008 | 2197 | 0.150 |
Why?
|
| Sanitary Engineering | 1 | 2016 | 3 | 0.140 |
Why?
|
| Antifungal Agents | 2 | 2020 | 749 | 0.140 |
Why?
|
| Genes, Bacterial | 7 | 1996 | 1071 | 0.140 |
Why?
|
| Silk | 1 | 2016 | 90 | 0.130 |
Why?
|
| Pseudomonas Infections | 2 | 2017 | 621 | 0.130 |
Why?
|
| Water Supply | 1 | 2016 | 206 | 0.130 |
Why?
|
| Contact Lenses, Hydrophilic | 2 | 2020 | 54 | 0.120 |
Why?
|
| Corneal Stroma | 1 | 2016 | 171 | 0.120 |
Why?
|
| Materials Testing | 2 | 2016 | 861 | 0.120 |
Why?
|
| Bacterial Proteins | 4 | 1996 | 3824 | 0.120 |
Why?
|
| Polymethyl Methacrylate | 2 | 2011 | 131 | 0.110 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2014 | 88 | 0.110 |
Why?
|
| Phototherapy | 1 | 2017 | 368 | 0.110 |
Why?
|
| Prosthesis Coloring | 1 | 2013 | 29 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 7403 | 0.110 |
Why?
|
| Lipoproteins | 1 | 1996 | 881 | 0.100 |
Why?
|
| Anterior Eye Segment | 1 | 2012 | 141 | 0.090 |
Why?
|
| Iris | 1 | 2012 | 231 | 0.090 |
Why?
|
| Tonometry, Ocular | 1 | 2011 | 235 | 0.090 |
Why?
|
| Telemetry | 1 | 2011 | 199 | 0.090 |
Why?
|
| Radio Waves | 1 | 2011 | 250 | 0.090 |
Why?
|
| Durapatite | 1 | 2011 | 163 | 0.090 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2012 | 191 | 0.090 |
Why?
|
| Cosmetic Techniques | 1 | 2012 | 148 | 0.090 |
Why?
|
| Tissue Scaffolds | 1 | 2016 | 926 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2017 | 1275 | 0.080 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2011 | 312 | 0.080 |
Why?
|
| Gene Expression Regulation, Bacterial | 3 | 1995 | 1130 | 0.080 |
Why?
|
| Fluorescein | 1 | 2009 | 174 | 0.080 |
Why?
|
| Uveitis | 1 | 2012 | 393 | 0.080 |
Why?
|
| Light | 1 | 2014 | 1345 | 0.070 |
Why?
|
| Mycobacterium chelonae | 1 | 2007 | 12 | 0.070 |
Why?
|
| Retinal Diseases | 1 | 2014 | 702 | 0.070 |
Why?
|
| Ciprofloxacin | 1 | 2009 | 312 | 0.070 |
Why?
|
| Tissue Engineering | 1 | 2016 | 1870 | 0.070 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2007 | 84 | 0.070 |
Why?
|
| Intraocular Pressure | 1 | 2011 | 1288 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1996 | 1903 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2016 | 1055 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2007 | 308 | 0.060 |
Why?
|
| Anti-Infective Agents | 2 | 2009 | 981 | 0.060 |
Why?
|
| Visual Acuity | 1 | 2014 | 2642 | 0.060 |
Why?
|
| Utah | 1 | 2023 | 131 | 0.050 |
Why?
|
| Retina | 1 | 2014 | 2635 | 0.050 |
Why?
|
| Incidence | 3 | 2023 | 21272 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 1996 | 7843 | 0.050 |
Why?
|
| Polymyxin B | 1 | 2020 | 44 | 0.050 |
Why?
|
| Benzalkonium Compounds | 1 | 2020 | 21 | 0.050 |
Why?
|
| Trimethoprim | 1 | 2020 | 83 | 0.050 |
Why?
|
| Humans | 14 | 2023 | 758406 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2020 | 1945 | 0.040 |
Why?
|
| Macrophages | 1 | 1993 | 5737 | 0.040 |
Why?
|
| Animals | 10 | 2020 | 167768 | 0.040 |
Why?
|
| Surgical Wound Infection | 1 | 2007 | 1526 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 2212 | 0.040 |
Why?
|
| Mycobacterium avium Complex | 1 | 2016 | 59 | 0.030 |
Why?
|
| Transformation, Bacterial | 1 | 1996 | 77 | 0.030 |
Why?
|
| Legionnaires' Disease | 1 | 2016 | 49 | 0.030 |
Why?
|
| Swine | 2 | 2020 | 5892 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 10652 | 0.030 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2016 | 76 | 0.030 |
Why?
|
| Legionella pneumophila | 1 | 2016 | 49 | 0.030 |
Why?
|
| Transcription Factors | 2 | 1993 | 12094 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2017 | 328 | 0.030 |
Why?
|
| Operon | 2 | 1995 | 370 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2020 | 2020 | 0.030 |
Why?
|
| DNA Transposable Elements | 2 | 1993 | 756 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2023 | 80168 | 0.030 |
Why?
|
| United States | 3 | 2023 | 72136 | 0.030 |
Why?
|
| Axons | 1 | 2022 | 1673 | 0.030 |
Why?
|
| Gene Library | 1 | 1996 | 1059 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2014 | 512 | 0.030 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 1993 | 39 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2013 | 18940 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2013 | 94 | 0.030 |
Why?
|
| Virulence | 2 | 1993 | 1298 | 0.030 |
Why?
|
| Silicone Elastomers | 1 | 2012 | 78 | 0.030 |
Why?
|
| Corneal Endothelial Cell Loss | 1 | 2012 | 25 | 0.030 |
Why?
|
| Epithelium | 2 | 1995 | 1605 | 0.030 |
Why?
|
| Transducers, Pressure | 1 | 2011 | 51 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 1993 | 306 | 0.020 |
Why?
|
| Risk Factors | 3 | 2014 | 73809 | 0.020 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2011 | 159 | 0.020 |
Why?
|
| Salmonella typhi | 1 | 1993 | 199 | 0.020 |
Why?
|
| Typhoid Fever | 1 | 1993 | 195 | 0.020 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2011 | 143 | 0.020 |
Why?
|
| Shear Strength | 1 | 2011 | 160 | 0.020 |
Why?
|
| Endothelium, Corneal | 1 | 2013 | 214 | 0.020 |
Why?
|
| Transducers | 1 | 2011 | 240 | 0.020 |
Why?
|
| Natamycin | 1 | 2009 | 3 | 0.020 |
Why?
|
| Alternaria | 1 | 2009 | 42 | 0.020 |
Why?
|
| Mutagenesis | 1 | 1993 | 1233 | 0.020 |
Why?
|
| Polyhydroxyethyl Methacrylate | 1 | 2009 | 30 | 0.020 |
Why?
|
| Amphotericin B | 1 | 2009 | 142 | 0.020 |
Why?
|
| Microscopy | 1 | 2014 | 884 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2014 | 1044 | 0.020 |
Why?
|
| Surface Properties | 1 | 2011 | 1159 | 0.020 |
Why?
|
| beta-Lactamases | 1 | 1990 | 304 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 1835 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 3733 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1993 | 2381 | 0.020 |
Why?
|
| Contact Lenses | 1 | 2009 | 138 | 0.020 |
Why?
|
| Polyglycolic Acid | 1 | 2009 | 405 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2009 | 697 | 0.020 |
Why?
|
| Device Removal | 1 | 2012 | 633 | 0.020 |
Why?
|
| Clarithromycin | 1 | 2007 | 85 | 0.020 |
Why?
|
| Repressor Proteins | 2 | 1995 | 2980 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1996 | 3680 | 0.020 |
Why?
|
| Candidiasis | 1 | 2009 | 363 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2013 | 10416 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1993 | 4624 | 0.020 |
Why?
|
| Escherichia coli | 2 | 1996 | 4215 | 0.020 |
Why?
|
| Corneal Transplantation | 1 | 2009 | 321 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2009 | 3991 | 0.020 |
Why?
|
| Myopia | 1 | 2007 | 245 | 0.010 |
Why?
|
| Female | 6 | 2023 | 390323 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1993 | 6209 | 0.010 |
Why?
|
| Male | 6 | 2023 | 358747 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2009 | 1133 | 0.010 |
Why?
|
| Adult | 5 | 2022 | 219935 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2013 | 4087 | 0.010 |
Why?
|
| Alkylating Agents | 1 | 1983 | 133 | 0.010 |
Why?
|
| Mutagens | 1 | 1983 | 178 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1993 | 5779 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2023 | 42062 | 0.010 |
Why?
|
| Mice | 3 | 2017 | 81101 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 6293 | 0.010 |
Why?
|
| Cell Line | 1 | 1993 | 15591 | 0.010 |
Why?
|
| Genotype | 1 | 1993 | 12945 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2007 | 1669 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22003 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1995 | 4169 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 18119 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 54137 | 0.010 |
Why?
|
| Aged | 3 | 2016 | 168218 | 0.010 |
Why?
|
| Boston | 1 | 2009 | 9304 | 0.010 |
Why?
|
| Young Adult | 1 | 2022 | 58808 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 39059 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1995 | 852 | 0.010 |
Why?
|
| Adolescent | 1 | 2022 | 87892 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 20055 | 0.010 |
Why?
|
| RNA, Bacterial | 1 | 1995 | 385 | 0.010 |
Why?
|
| 4-Nitroquinoline-1-oxide | 2 | 1983 | 17 | 0.010 |
Why?
|
| Methyl Methanesulfonate | 2 | 1983 | 28 | 0.010 |
Why?
|
| Middle Aged | 2 | 2022 | 219568 | 0.010 |
Why?
|
| Ethyl Methanesulfonate | 2 | 1983 | 29 | 0.010 |
Why?
|
| Base Sequence | 2 | 1995 | 12436 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 1993 | 374 | 0.010 |
Why?
|
| Vaccines, Attenuated | 1 | 1993 | 314 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1995 | 13447 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 2753 | 0.010 |
Why?
|
| Endocytosis | 1 | 1995 | 958 | 0.010 |
Why?
|
| Mutation | 3 | 1993 | 29915 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 1990 | 160 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 58683 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 17617 | 0.010 |
Why?
|
| DNA Probes | 1 | 1990 | 543 | 0.010 |
Why?
|
| Species Specificity | 1 | 1993 | 2417 | 0.000 |
Why?
|
| Child | 1 | 2016 | 79818 | 0.000 |
Why?
|
| Ultraviolet Rays | 2 | 1983 | 1076 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2009 | 41256 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1995 | 4711 | 0.000 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 1983 | 18 | 0.000 |
Why?
|
| Methylnitrosourea | 1 | 1983 | 30 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1995 | 3664 | 0.000 |
Why?
|
| Genetic Vectors | 1 | 1993 | 3380 | 0.000 |
Why?
|
| Kinetics | 1 | 1990 | 6371 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2009 | 64378 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1995 | 7590 | 0.000 |
Why?
|
| Chromosomes, Bacterial | 1 | 1981 | 280 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1995 | 12759 | 0.000 |
Why?
|
| Recombination, Genetic | 1 | 1983 | 1526 | 0.000 |
Why?
|
| DNA Repair | 1 | 1983 | 2038 | 0.000 |
Why?
|
| Models, Genetic | 1 | 1983 | 3441 | 0.000 |
Why?
|
Concepts
(214)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(29)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_